Thinking of joining a study?

Register your interest

NCT06581029 | NOT YET RECRUITING | SLE


Evaluating Mental Health Challenges in Juvenile Lupus Erythematosus and Their Caregivers
Sponsor:

Assiut University

Information provided by (Responsible Party):

Sahar Samir Farghly Badran

Brief Summary:

assessment of psychiatric problems in pediatric SLE and their caregivers. evaluate the possible risk factors of psychiatric problems such as peer victimization, academic performance, fatigue, self-esteem and quality of life.

Condition or disease

SLE

Intervention/treatment

The multidimensional peer victimization scale (PVS)

Detailed Description:

Juvenile-onset systemic lupus erythematosus (jSLE) is a rare but severe multisystem autoimmune disease which may cause significant damage, disability, and death . Juvenile SLE patients constitute 15-20% of all SLE cases . Compared to the adult SLE, jSLE patients have higher morbidity and mortality rates. Renal, cardiovascular, and neuropsychiatric (NP) involvements are the most important reasons for morbidity and mortality . Therefore, knowledge of common mental illnesses such as major depressive disorder (MDD) and anxiety disorders in cSLE may be limited. Establishing the prevalence of MDD and anxiety in cSLE is important , as comorbidity rates of these disorders may be increased in cSLE for several reasons. First, the diagnosis of a serious physical health condition confers psychological vulnerability to feelings of sadness, helplessness, stress, and worry about the future.9 For some individuals, such symptoms warrant further evaluation and may persist beyond the initial adjustment period and reach clinical significance, requiring therapeutic intervention. SLE carries a patient-treatment burden similar to other chronic diseases. Such treatment burden places susceptible individuals at risk of psychiatric disorder. Second, although depressed mood may present in the absence of active CNS disease, it may also occur as a symptom of neuropsychiatric c SLE (NPSLE), yielding clinically significant treatment implications. Third, treatment of SLE with known depressogenic medications like steroid may lead to depressive symptom elevation or exacerbate a co-morbid primary MDD. Moreover, among patients with depressed mood as a manifestation of NPSLE, the initiation of steroid treatment may worsen depressive symptoms. It is unclear whether such risks are observed in the cSLE population.

Study Type : OBSERVATIONAL
Estimated Enrollment : 62 participants
Official Title : Evaluating Mental Health Challenges in Juvenile Lupus Erythematosus and Their Caregivers
Actual Study Start Date : 2025-06-01
Estimated Primary Completion Date : 2026-06-01
Estimated Study Completion Date : 2026-12-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 11 Years to 18 Years
Sexes Eligible for Study: ALL
Criteria
Inclusion Criteria
  • 1. Age from 11 to 18 years
  • 2. Both sex
  • 3. diagnosed with SLE for at least 6 months to allow for an adjustment period following diagnosis.
  • 4. Met the New ACR and EULAR criteria for classification of SLE .
  • Inclusion criteria of the control healthy group : 1- no history of psychiatric and medical disease 2-Intelligence quotation more than 70.
Exclusion Criteria
  • 1. No history of psychiatric illness prior to the diagnosis of lupus.
  • 2. Intelligence quotation more than 70.

Evaluating Mental Health Challenges in Juvenile Lupus Erythematosus and Their Caregivers

Location Details

NCT06581029


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


No Location Found

Loading...